PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29504721
OWN - NLM
STAT- MEDLINE
DCOM- 20180312
LR  - 20180312
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 9
DP  - 2018 Mar 1
TI  - Durvalumab in Stage III Non-Small-Cell Lung Cancer.
PG  - 869
LID - 10.1056/NEJMc1716426 [doi]
FAU - Santoni, Matteo
AU  - Santoni M
AD  - Macerata Hospital, Macerata, Italy
AD  - [email protected]
FAU - Battelli, Nicola
AU  - Battelli N
AD  - Macerata Hospital, Macerata, Italy
FAU - Buti, Sebastiano
AU  - Buti S
AD  - University Hospital of Parma, Parma, Italy
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (durvalumab)
SB  - AIM
SB  - IM
CON - N Engl J Med. 2017 Nov 16;377(20):1919-1929. PMID: 28885881
CIN - N Engl J Med. 2018 Mar 1;378(9):868-870. PMID: 29490170
MH  - Antibodies, Monoclonal
MH  - B7-H1 Antigen
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - Combined Modality Therapy
MH  - Humans
MH  - *Lung Neoplasms
MH  - Neoplasm Staging
EDAT- 2018/03/06 06:00
MHDA- 2018/03/13 06:00
CRDT- 2018/03/06 06:00
PHST- 2018/03/06 06:00 [entrez]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/03/13 06:00 [medline]
AID - 10.1056/NEJMc1716426#SA2 [pii]
AID - 10.1056/NEJMc1716426 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Mar 1;378(9):869. doi: 10.1056/NEJMc1716426.